Anivive_PPNuture_eblast

#6c6c7e #394d5d {{custommediaemailsadvanced::eyebrow_copy}} {{custommediaemailsadvanced::eyebrow_background_color}} {{custommediaemailsadvanced::eyebrow_text_color}} {{custommediaemailsadvanced::is_partner_podcast}} {{custommediaemailsadvanced::partner_podcast_buttons_lead_in_text}} {{custommediaemailsadvanced::partner_podcast_spotify_url}} {{custommediaemailsadvanced::partner_podcast_apple_url}} {{custommediaemailsadvanced::partner_podcast_google_url}} /uploads/anivive_pp_nuture_artboard_96_2_x-2518860666bdf0e895f35a720021cd6a.jpg {{custommediaemailsadvanced::logo_self_hosted}} 72 {{custommediaemailsadvanced::logo_height}} 20px 40px 20px {{custommediaemailsadvanced::logo_alt_text}} {{custommediaemailsadvanced::logo_url}} {{custommediaemailsadvanced::no_border_under_logo}} {{custommediaemailsadvanced::apply_logo_over_background_image}} true /uploads/anivive_pp_nuture_artboard_96_2_x-f19a41bb8fa5d8deedfe098bd3cb06a8.jpg {{custommediaemailsadvanced::desktop_header_image_alt}} {{custommediaemailsadvanced::desktop_header_image_alt_1x}} true true {{custommediaemailsadvanced::mobile_header_image}} {{custommediaemailsadvanced::mobile_header_image_alt}} {{custommediaemailsadvanced::add_left_right_padding_to_header_image}} {{custommediaemailsadvanced::add_bottom_padding_to_header_image}} {{custommediaemailsadvanced::add_top_padding_to_header_image}} {{custommediaemailsadvanced::header_image_padding_background_color}} {{custommediaemailsadvanced::scale_mobile_header_image}} {{custommediaemailsadvanced::background_height}} #000000 {{custommediaemailsadvanced::headline_image}} {{custommediaemailsadvanced::headline_image_self_hosted}} {{custommediaemailsadvanced::headline_url}} 480 379 {{custommediaemailsadvanced::headline_image_custom_css}} {{custommediaemailsadvanced::place_headline_image_above_header_image}} {{custommediaemailsadvanced::place_headline_image_below_header_image}} {{custommediaemailsadvanced::spacer_image}} {{custommediaemailsadvanced::spacer_image_self_hosted}} 600 {{custommediaemailsadvanced::spacer_image_height}} {{custommediaemailsadvanced::spacer_image_scale_desktop_padding_bottom}} {{custommediaemailsadvanced::spacer_image_scale_mobile_padding_bottom}} {{custommediaemailsadvanced::subhead_copy}} {{custommediaemailsadvanced::large_subhead_copy}} {{custommediaemailsadvanced::subhead_td_custom_css}} {{custommediaemailsadvanced::subhead_span_custom_css}} {{custommediaemailsadvanced::horizontal_rule_under_subhead}} {{custommediaemailsadvanced::intro_copy}} {{custommediaemailsadvanced::intro_centered}} {{custommediaemailsadvanced::intro_copy_td_custom_css}} {{custommediaemailsadvanced::intro_copy_span_custom_css}} {{custommediaemailsadvanced::horizontal_rule_under_intro}}

Sadie’s owners declined referral, and Scout had stopped chemotherapy—but that didn’t halt their treatment options. This step{nbh}by{nbh}step flow chart is here to show how primary care teams can help more canine lymphoma patients—no matter where they are in their cancer journey. 

{{custommediaemailsadvanced::custom_body_text_color}} #f3f6f8 padding-top:30px; padding-left: 50px; padding-right: 50px; {{custommediaemailsadvanced::body_span_custom_css}} {{custommediaemailsadvanced::custom_body_horizontal_rule_color}} {{custommediaemailsadvanced::ordered_list_bullet_1}} 1 {{custommediaemailsadvanced::custom_icon_1}} {{custommediaemailsadvanced::custom_icon_1_self_hosted}} {{custommediaemailsadvanced::custom_icon_1_width}} {{custommediaemailsadvanced::ordered_list_bullet_2}} 2 {{custommediaemailsadvanced::custom_icon_2}} {{custommediaemailsadvanced::custom_icon_2_self_hosted}} {{custommediaemailsadvanced::custom_icon_2_width}} {{custommediaemailsadvanced::ordered_list_bullet_3}} 3 {{custommediaemailsadvanced::custom_icon_3}} {{custommediaemailsadvanced::custom_icon_3_self_hosted}} {{custommediaemailsadvanced::custom_icon_3_width}} {{custommediaemailsadvanced::ordered_list_bullet_4}} 4 {{custommediaemailsadvanced::custom_icon_4}} {{custommediaemailsadvanced::custom_icon_4_self_hosted}} {{custommediaemailsadvanced::custom_icon_4_width}} {{custommediaemailsadvanced::ordered_list_bullet_5}} 5 {{custommediaemailsadvanced::custom_icon_5}} {{custommediaemailsadvanced::custom_icon_5_self_hosted}} {{custommediaemailsadvanced::custom_icon_5_width}} #000000 {{custommediaemailsadvanced::center_icons_in_mobile}} {{custommediaemailsadvanced::ordered_list_bullet_td_custom_css}} {{custommediaemailsadvanced::ordered_list_bullet_span_custom_css}} {{custommediaemailsadvanced::body_2_copy}} {{custommediaemailsadvanced::body_2_td_custom_css}} {{custommediaemailsadvanced::body_2_span_custom_css}} {{custommediaemailsadvanced::closing_emphasis_copy}} {{custommediaemailsadvanced::closing_emphasis_link_text}} {{custommediaemailsadvanced::closing_emphasis_link_url}} {{custommediaemailsadvanced::closing_emphasis_link_color}} {{custommediaemailsadvanced::closing_emphasis_td_custom_css}} {{custommediaemailsadvanced::closing_emphasis_span_custom_css}} background-color: #394d5d; Explore how{br}LAVERDIA{nbh}CA1 can help{br}your patients{nbs}today {{custommediaemailsadvanced::cta_line_1_custom_text_color}} true {{custommediaemailsadvanced::cta_line_2}} {{custommediaemailsadvanced::cta_line_2_custom_text_color}} {{custommediaemailsadvanced::cta_line_2_link}} Get started #6c6c7e {{custommediaemailsadvanced::custom_button_text_color}} https://www.cliniciansbrief.com/laverdia-ca1-effective-medicine-all-your-lymphoma-patients {{custommediaemailsadvanced::footnote}} {{custommediaemailsadvanced::large_footnote_copy}} {{custommediaemailsadvanced::footnote_td_custom_css}} {{custommediaemailsadvanced::footnote_span_custom_css}}

Laverdia{nbh}CA1 is conditionally approved by FDA for the treatment of lymphoma in dogs pending a full demonstration of effectiveness under application number 141{nbh}526.

{{custommediaemailsadvanced::pre_footer_center}}

{{custommediaemailsadvanced::preview_text}}

{{custommediaemailsadvanced::preview_text}}